Abstract
Purpose: To determine the diagnostic performance of parenchymal MRI features differentiating CP from controls. Methods: This prospective study performed abdominal MRI scans at seven institutions, using 1.5 T Siemens and GE scanners, in 50 control and 51 definite CP participants, from February 2019 to May 2021. MRI parameters included the T1-weighted signal intensity ratio of the pancreas (T1 score), arterial-to-venous enhancement ratio (AVR) during venous and delayed phases, pancreas volume, and diameter. We evaluated the diagnostic performance of these parameters individually and two semi-quantitative MRI scores derived using logistic regression: SQ-MRI Model A (T1 score, AVR venous, and tail diameter) and Model B (T1 score, AVR venous, and volume). Results: When compared to controls, CP participants showed a significantly lower mean T1 score (1.11 vs. 1.29), AVR venous (0.86 vs. 1.45), AVR delayed (1.07 vs. 1.57), volume (54.97 vs. 80.00 ml), and diameter of the head (2.05 vs. 2.39 cm), body (2.25 vs. 2.58 cm), and tail (1.98 vs. 2.51 cm) (p < 0.05 for all). AUCs for these individual MR parameters ranged from 0.66 to 0.79, while AUCs for the SQ-MRI scores were 0.82 and 0.81 for Model A (T1 score, AVR venous, and tail diameter) and Model B (T1 score, AVR venous, and volume), respectively. After propensity-matching adjustments for covariates, AUCs for Models A and B of the SQ-MRI scores increased to 0.92 and 0.93, respectively. Conclusion: Semi-quantitative parameters of the pancreatic parenchyma, including T1 score, enhancement ratio, pancreas volume, diameter and multi-parametric models combining these parameters are helpful in diagnosis of CP. Longitudinal analyses including more extensive population are warranted to develop new diagnostic criteria for CP. Graphical abstract: [Figure not available: see fulltext.].
Original language | English |
---|---|
Pages (from-to) | 3162-3173 |
Number of pages | 12 |
Journal | Abdominal Radiology |
Volume | 48 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2023 |
Bibliographical note
Publisher Copyright:© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Funding
Research reported in this publication was supported by National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award numbers related to: the MINIMAP study (R01DK116963) and The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) under award numbers: U01DK108328 (CDMC), U01DK108323 (IU), U01DK108306 (UPMC), U01DK108327 (OSU), U01DK108327 (CSMC), DKP3041301 (UCLA), U01DK108300 (Stanford) and U01DK108288 (Mayo Clinic). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funders | Funder number |
---|---|
CDMC | |
CPDPC | |
CSMC | DKP3041301 |
National Institutes of Health (NIH) | |
National Childhood Cancer Registry – National Cancer Institute | |
National Institute of Diabetes and Digestive and Kidney Diseases | U01DK108323 |
Mayo Clinic Rochester | |
University of California, Los Angeles | U01DK108300, U01DK108288 |
University of Pittsburgh Medical Center | U01DK108327 |
Pancreatic Cancer Action Network | |
Division of Diabetes, Endocrinology, and Metabolic Diseases | U01DK108306, U01DK108328, R01DK116963 |
Keywords
- Chronic pancreatitis
- Enhancement
- MRI
- Size
- T1
- Volume
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
- Radiology Nuclear Medicine and imaging
- Gastroenterology
- Urology